Literature DB >> 8405237

Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals.

A Prieto1, J Garcia-Suarez, E Reyes, P Lapeña, M Hernandez, M Alvarez-Mon.   

Abstract

T lymphocytes from patients with B cell chronic lymphocytic leukemia (B-CLL) exhibit defective proliferative response to plant lectins. The blastogenic response of purified T lymphocytes to signals that interact with membrane molecules (phytohemagglutinin [PHA], anti-CD3 monoclonal antibody [MAB]) and with the intracytoplasmic protein kinase C (PKC) was investigated in 22 B-CLL patients and 18 healthy controls. 3H-thymidine uptake in T lymphocytes from 14 of 22 B-CLL patients after PHA, anti-CD3, and phorbol myristate acetate (PMA) was found to be lower than in the healthy controls. This defective proliferative response was not corrected by the exogenous addition of interleukin-2 (IL-2) to the culture medium. In analyzing the cell cycle progression of these T lymphocytes from B-CLL patients, we found that the percentage of cells in S phase at 2 days of PHA stimulation was significantly decreased and that it was normalized after 5 days of culture. Defective response of T lymphocytes from B-CLL patients to polyclonal mitogens was observed in those patients with advanced disease (stages A, B, and C). However, this T cell proliferative response was normal in patients with "smoldering B-CLL." We conclude that the defective proliferative response to membrane and intracytoplasmatic mitogenic signals on T lymphocytes from a part of B-CLL patients can be ascribed to delayed activation and cell-cycle progression, and an association between the alterations in the T cell compartment of B-CLL patients and the progression of the disease may be suggested.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405237

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  3 in total

1.  Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).

Authors:  N Porakishvili; T Roschupkina; T Kalber; A P Jewell; K Patterson; K Yong; P M Lydyard
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

Review 2.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.

Authors:  K Kondo; H Shaim; P A Thompson; J A Burger; M Keating; Z Estrov; D Harris; E Kim; A Ferrajoli; M Daher; R Basar; M Muftuoglu; N Imahashi; A Alsuliman; C Sobieski; E Gokdemir; W Wierda; N Jain; E Liu; E J Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-10-03       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.